The inhibition of Gln uptake is currently being studied as a potential therapeutic tool for AML therapy.30,31 Therefore, a future combination therapy of SETD1A inhibition and Gln uptake inhibition could represent an approach for AML treatment. This evidence concerns the gene SETD1A and acute myeloid leukemia.